Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 3 Major Bleeding and Angiographic Complications
Major bleeding 48 h after PCI and angiographic complications, according to use of protocol-specified UFH in the enoxaparin group. If PCI was performed within 6 h of the last subcutaneous enoxaparin dose, no additional UFH was given. If PCI was performed after 6 h from the last subcutaneous enoxaparin dose, supplemental UFH was administered for the PCI. Major bleeding was reduced with fondaparinux irrespective of whether UFH was used in the enoxaparin group. Angiographic complications were reduced when UFH was used for the PCI procedure compared with either fondaparinux alone or with enoxaparin alone. CI = confidence interval; RR = relative risk; other abbreviations as in Figure 1.
|
